The Fast Track designation meaningfully de-risks CDI-988's development path and could accelerate its timeline to market. Given COCP's $14M market cap, this represents a significant value inflection point. Traders should monitor upcoming clinical data from the Phase 1b study and future FDA interactions as potential catalysts.
Price Chart
Executive Summary
Cocrystal Pharma received FDA Fast Track designation for CDI-988, its oral antiviral candidate for norovirus treatment and prevention. This designation enables accelerated development, rolling NDA review, and more frequent FDA interactions, marking a significant regulatory milestone for the clinical-stage biotech.
Key Facts
- FDA granted Fast Track designation to CDI-988 for norovirus infection treatment and prophylaxis
- CDI-988 is the first oral antiviral candidate being developed for norovirus
- Fast Track status allows for rolling NDA review and more frequent FDA communication
- A Phase 1b norovirus challenge study is currently underway at Emory University School of Medicine
- Norovirus causes an estimated 685 million global cases annually with $60 billion in economic impact
Financial Impact
No direct financial impact disclosed, but Fast Track designation increases the probability of regulatory success and potential commercialization for CDI-988
Risk Factors
- CDI-988 is still in early-stage development with no guarantee of clinical success
- The company faces typical biotech risks including funding needs, clinical trial delays, and regulatory hurdles
- Market cap remains small at $14M, indicating high volatility and execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-014819 |
| Exhibit: ex99-1.htm | 0001493152-26-014819 |
| Document: 0001493152-26-014819-index-headers.html | 0001493152-26-014819 |
| Document: 0001493152-26-014819-index.html | 0001493152-26-014819 |
| Document: 0001493152-26-014819.txt | 0001493152-26-014819 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $1.24 | awaiting T+60 | — | $0.9700 (−21.77%) |
Aug 3, 2026 12w ago | 8-K | $0.9400 | awaiting T+60 | — | $0.9700 (+3.19%) |
Jun 9, 2026 20w ago | 8-K | $1.02 $1.16 | ▲ +13.73% | ▲ +9.91% | $0.9700 (−4.90%) |
Jun 3, 2026 20w ago | 8-K | $1.06 $1.14 | ▲ +7.55% | ▲ +5.05% | $0.9700 (−8.49%) |
May 27, 2026 21w ago | DEFA14A | $1.13 $1.15 | ▲ +1.77% | ▲ +0.03% | $0.9700 (−14.16%) |
May 26, 2026 22w ago | 8-K | $1.13 $1.15 | ▲ +1.33% | ▼ −1.40% | $0.9700 (−14.16%) |
May 15, 2026 23w ago | Press Release | $1.20 $1.08 | ▼ −10.00% | ▼ −14.52% | $0.9700 (−19.17%) |
May 4, 2026 25w ago | EFFECT | $1.31 $0.8703 | ▲ +33.56% | ▲ +35.42% | $0.9700 (+25.95%) |
Apr 2, 2026 29w ago | 8-K | $1.51 $1.05 | ▼ −30.46% | ▼ −44.62% | $0.9700 (−35.76%) |
Mar 31, 2026 30w ago | 8-K | $1.01 $1.02 | ▲ +0.99% | ▼ −11.39% | $0.9700 (−3.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers